Evidence map›Paper›PMID 34026332›Full record

ArticleOncoimmunology2021

Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.

Xin-Wen Zhang, Katrin Huck, Kristine Jähne, Frederik Cichon, Jana K Sonner, Friederike Ufer, Simone Bauer, Marcel Seungsu Woo, Ed Green, Kevin Lu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Xin-Wen ZhangDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Katrin HuckDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Kristine JähneDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Frederik CichonDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Jana K SonnerDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Friederike UferInstitute of Neuroimmunology Und Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Simone BauerInstitute of Neuroimmunology Und Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Marcel Seungsu WooInstitute of Neuroimmunology Und Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ed GreenDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Kevin LuDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Michael KilianDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Manuel A FrieseInstitute of Neuroimmunology Und Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Michael PlattenDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Katharina SahmDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEUniversität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity Medical Centre Mannheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cell (DC) vaccination has proven to be an effective and safe adjuvant for cancer immunotherapies. As the presence of DCs within the tumor microenvironment promotes adaptive antitumor immunity, enhancement of DC migration toward the tumor microenvironment following DC vaccination might represent one possible approach to increase its therapeutic efficacy. While recent findings suggest the activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) as critical regulator of DC migration in the context of autoimmune diseases, we aimed to investigate the impact of Arc/Arg3.1 expression for DC-based cancer vaccines. To this end, DC migration capacity as well as the induction of T cell-mediated antitumor immunity was assessed in an experimental B16 melanoma model with

Indexed as

Cancer VaccinesMelanoma, ExperimentalAnimalsCytoskeletonDendritic CellsMiceMice, Inbred C57BLTumor MicroenvironmentVaccinationCancer VaccinesAdoptive immunotherapyCD8-positive T-lymphocytesdendritic cellsmelanomatumor microenvironment

Identifiers

PMID34026332
PMCPMC8128181
OpenAlexW3161213164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.